PACIFIC BIOSCIENCES OF CALIF (PACB)

US69404D1081 - Common Stock

1.99  +0.19 (+10.56%)

After market: 1.99 0 (0%)

Fundamental Rating

2

Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 56 industry peers in the Life Sciences Tools & Services industry. PACB has a bad profitability rating. Also its financial health evaluation is rather negative. PACB is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PACB has reported negative net income.
PACB had a negative operating cash flow in the past year.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -27.19%, PACB is not doing good in the industry: 73.21% of the companies in the same industry are doing better.
The Return On Equity of PACB (-87.01%) is worse than 82.14% of its industry peers.
Industry RankSector Rank
ROA -27.19%
ROE -87.01%
ROIC N/A
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 23.81%, PACB is doing worse than 76.79% of the companies in the same industry.
In the last couple of years the Gross Margin of PACB has declined.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PACB has more shares outstanding
The number of shares outstanding for PACB has been increased compared to 5 years ago.
Compared to 1 year ago, PACB has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.90, we must say that PACB is in the distress zone and has some risk of bankruptcy.
PACB's Altman-Z score of -1.90 is on the low side compared to the rest of the industry. PACB is outperformed by 85.71% of its industry peers.
PACB has a Debt/Equity ratio of 1.97. This is a high value indicating a heavy dependency on external financing.
PACB has a Debt to Equity ratio of 1.97. This is amonst the worse of the industry: PACB underperforms 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Altman-Z -1.9
ROIC/WACCN/A
WACC6.97%

2.3 Liquidity

A Current Ratio of 9.74 indicates that PACB has no problem at all paying its short term obligations.
PACB's Current ratio of 9.74 is amongst the best of the industry. PACB outperforms 87.50% of its industry peers.
A Quick Ratio of 8.64 indicates that PACB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 8.64, PACB belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 8.64

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PACB have decreased strongly by -14.96% in the last year.
Looking at the last year, PACB shows a small growth in Revenue. The Revenue has grown by 2.15% in the last year.
The Revenue has been growing by 20.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Sales Q2Q%-28.23%

3.2 Future

The Earnings Per Share is expected to grow by 11.44% on average over the next years. This is quite good.
PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.12% yearly.
EPS Next Y-9.17%
EPS Next 2Y19.92%
EPS Next 3Y15.29%
EPS Next 5Y11.44%
Revenue Next Year-21.98%
Revenue Next 2Y-2.61%
Revenue Next 3Y7.43%
Revenue Next 5Y13.12%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PACB's earnings are expected to grow with 15.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.92%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (1/3/2025, 8:00:02 PM)

After market: 1.99 0 (0%)

1.99

+0.19 (+10.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners85.81%
Inst Owner Change-4.42%
Ins Owners0.59%
Ins Owner Change-1.95%
Market Cap544.98M
Analysts75.45
Price Target2.92 (46.73%)
Short Float %21.37%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-82.9%
Min EPS beat(2)-169.73%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-43.9%
Min EPS beat(4)-169.73%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-18.18%
EPS beat(12)4
Avg EPS beat(12)-13.99%
EPS beat(16)7
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-10.12%
Min Revenue beat(2)-13.63%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-8.04%
Min Revenue beat(4)-13.63%
Max Revenue beat(4)-0.47%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)4
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)0.8%
PT rev (1m)0%
PT rev (3m)1.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.73%
EPS NY rev (1m)5.22%
EPS NY rev (3m)5.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-23.19%
Revenue NY rev (1m)-0.63%
Revenue NY rev (3m)-6.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.15
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.63
BVpS1.65
TBVpS-1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.19%
ROE -87.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.81%
FCFM N/A
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.96%
Cap/Sales 3.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 8.64
Altman-Z -1.9
F-Score3
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)95.34%
Cap/Depr(5y)68.25%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
EPS Next Y-9.17%
EPS Next 2Y19.92%
EPS Next 3Y15.29%
EPS Next 5Y11.44%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Sales Q2Q%-28.23%
Revenue Next Year-21.98%
Revenue Next 2Y-2.61%
Revenue Next 3Y7.43%
Revenue Next 5Y13.12%
EBIT growth 1Y3.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.04%
EBIT Next 3Y16.29%
EBIT Next 5Y13.5%
FCF growth 1Y3.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.59%
OCF growth 3YN/A
OCF growth 5YN/A